Compare The Vita Coco Company Inc (COCO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Vita Coco Company Inc vs Zimmer Biomet Holdings Inc — how do they compare? The Vita Coco Company Inc trades at $74.45 (market cap $4.23B), while Zimmer Biomet Holdings Inc trades at $90.42 (market cap $17.61B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.2× The Vita Coco Company Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.05% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| COCO | ZBH | |
|---|---|---|
Market Cap | $4.23B | $17.61B |
Sector | Technology | Health |
52-Week High | $84.02 | $107.71 |
52-Week Low | $32.30 | $79.58 |
Enterprise Value | $4.04B | $24.66B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COCO trades at $74.635, up 4.53% today, with a bullish technical signal and strong earnings momentum after beating Q1 2026 EPS estimates. The company reported 37% YoY revenue growth in Q1 2026, with management raising full-year guidance. Analysts maintain a $78.00 consensus price target, with 60% recommending Buy. Key support lies at $72, with resistance at $76.
Outlook remains positive driven by international expansion and dominant market position, but elevated valuation multiples pose risks. Upside depends on sustained execution against raised guidance, while any earnings miss or margin pressure could trigger volatility. The stock offers growth exposure but requires monitoring of competitive and consumer spending trends.
Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.
ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
